Pierre Fabre announces the gradual return to normality of his businessafter being the victim of a cyberattack
3 May 2021
Castres, April 30, 2021 -Following the cyberattack suffered by the Pierre Fabre Group on March 31, computer remediation operations have allowed the gradual return to normality of the company's main operations.
After the restart of effective distribution activities since 15 April, the Group's main industrial sites located in Gien (drugs), Soual (dermo-cosmetics) and Avène (dermo-cosmetics) have gradually restarted their industrial production since Monday 26 April. Gaillac's pharmaceutical and dermo-cosmetic asset manufacturing plant was able to continue its operations.
In France and internationally, commercial activity has never been interrupted and distribution operations have now resumed normally in alltheGroup's subsidiaries.
Thanks to safety stocks and the continuation of priority deliveries, the Group has been able to ensure the continuity of the availabilityof its therapeutic treatments to patients. In addition, stocks of dermo-cosmetic products held by wholesalers, distributors and pharmacists were generally sufficient to absorb the consumer demand.
As a precautionary measure, and in accordance with its forecast risk management plan, the Group's computer system was immediately put on standby to prevent the spread of the virus. Customers, partners and health authorities were regularly kept informed of the situation and a complaint was filed, the attack having been claimed.
As part of the remediation operations, all of the Group's information systems and IT media were reviewed to check or restore their integrity and to strengthen their security.
Pierre Fabre would like to thank his partners and his teams for their exceptional commitment and resilience that allow the Recovery Plan to run smoothly. The group also apologises to its customers for the inconvenience caused by this cyberattack in their commercial and partnership relationships.
About Pierrre Fabre
“Pierre Fabre is the 2nd largest dermo-cosmetics laboratory in the world, the 2ndlargest private French pharmaceutical group and the market leader in France for products sold over the counter in pharmacies. Its portfolio includes several medical franchises and international brands including Pierre Fabre Oncology, Pierre Fabre Dermatology, Eau Thermale Avène, Klorane, Ducray, René Furterer, A-Derma, Naturactive, Pierre Fabre Oral Care.
In 2020, Pierre Fabre generated €2.3 billion in revenues, 65% of which came from international sales. Established in the Occitanie region since its creation, and manufacturing over 95% of its products in France, the Group employs some 10,000 people worldwide. Its products are distributed in about 130 countries.
Pierre Fabre is 86%-owned by the Pierre Fabre Foundation, a government-recognised public-interest foundation, and secondarily by its own employees through an international employee stock ownership plan.In 2019, Ecocert Environment assessed the Group’s corporate social and environmental responsibility approach according to the ISO 26000 standard on sustainable development and awarded it the ECOCERT 26000 “Excellence” level.
Further information aboutPierre Fabre can be found at www.pierre-fabre.com, @PierreFabre.
Contacts presse Pierre Fabre
+33(0)6 09 22 29 67